NCT06525935

A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered for 48 Weeks to Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 469 (actual)
• Sponsor: Carmot Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants with obesity or who are overweight with at least one weight-related comorbidity.

Conditions

• Obesity
• Overweight

Interventions

Type	Name	Description
DRUG	Placebo	Placebo will be volume- matched and administered subcutaneously (SC) once weekly.
DRUG	Enicepatide	Enicepatide will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.

Timeline

• Start date: 2024-08-16
• Primary completion: 2025-12-08
• Completion: 2025-12-08
• First posted: 2024-07-29
• Last updated: 2026-04-17

Locations

34 sites across 1 country: United States

Regulatory

• FDA-regulated drug study